BriaCell Therapeutics Corp.

09/02/2026

BriaCell is expanding its personalized, cell-based approach across multiple cancer indications.

In a new Inside Precision Medicine article, Bria-MEL+, BriaCell's personalized whole cell immunotherapy vaccine candidate is highlighted alongside BriaCell’s Phase 3 trial of Bria-IMT™ in metastatic breast cancer and Bria-PROS+ in prostate cancer.

Read more: https://bit.ly/46u9Guc

BriaCell has that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a “key genetic engineering milestone, advancing the program toward clinical development."

09/02/2026

“The future of cellular oncology lies in off-the-shelf, targeted platforms.”

In a new PharmaPhorum article, BriaCell President & CEO William V. Williams examines the innovation gap in oncology and the need for scalable approaches to cellular immunotherapy.

The article explores how off-the-shelf cell platforms could reduce production costs, lower health system burdens and eliminate critical treatment delays, while next-generation whole-cell and platform approaches may help address the complex, immunosuppressive environments of solid tumours.

Dr. Williams also discusses adaptive clinical trial protocols and the importance of aligning early clinical strategies with the realities of late-stage development and commercialisation.

Read the full article: https://bit.ly/4ygcKWD

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

09/01/2026

Explore Your Next Opportunity at BriaCell.

At BriaCell Therapeutics, our team is working to advance innovative cancer treatments and make a meaningful impact in oncology.

Current openings include:

• Scientist/Senior Scientist – QC – Philadelphia, USA
• Scientist (Translational Biomarkers & Immunomonitoring)
• Clinical Research Associate Intern

Interested in being part of the team? View open positions and learn more: briacell.com/careers/

08/31/2026

September is Prostate Cancer Awareness Month, a timely reminder of the urgent need for advanced treatment options.

With FDA clearance of our IND application for Bria-PROS+™, our team is preparing to initiate a Phase 1/2a clinical trial. Bria-PROS+™ is our next-generation, off-the-shelf, personalized cell-based immunotherapy designed to activate the body's immune system against advanced prostate cancer.

As September approaches, our commitment to delivering innovative immuno-oncology solutions to patients who need them most is stronger than ever.

Learn more here: https://bit.ly/4fNH4An

08/28/2026

ICYMI: BriaCell is advancing Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate, toward clinical development following a key genetic engineering milestone.

Bria-MEL+ is designed to be personalized yet “off-the-shelf”: a simple patient saliva test will determine which of several premanufactured treatment cell lines will be selected for personalized treatment, avoiding the need to manufacture a unique product for each individual patient.

For more: https://bit.ly/4xjGX7p

08/28/2026

As personalized cancer vaccines gain momentum, BriaCell is advancing a distinct approach with Bria-MEL+.

As highlighted by Inside Precision Medicine, Bria-MEL+ is designed as a personalized, off-the-shelf cellular immunotherapy for melanoma—using a simple saliva test to identify the premanufactured cell line selected through patient HLA matching.

Read the full article: https://bit.ly/46u9Guc

BriaCell has that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a “key genetic engineering milestone, advancing the program toward clinical development."

08/27/2026

Approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime, making it the second most common cancer among men in the United States.

As Prostate Cancer Awareness Month approaches, bringing attention to early detection, continuous research, and innovative treatment options is more important than ever.

While early-stage prostate cancer has a high survival rate, advanced and metastatic forms present significant challenges that demand next-generation solutions.

This September, we join patients, advocates, and researchers worldwide in raising awareness and driving progress in immuno-oncology.

08/27/2026

What BriaCell’s trial design says about real-world cancer research:

In a conversation with Clinical Leader Executive Editor Abby Proch, BriaCell President & CEO William Williams, MD, FACP, discusses how the company designed its Phase 3 trial of Bria-IMT™ in metastatic breast cancer.

The discussion also explores the use of treatment of physician’s choice as a control arm and how real-world considerations shaped the trial design.

Read the full interview: [https://bit.ly/3CgzknU

08/26/2026

Help Shape the Future of Cancer Treatment!

BriaCell Therapeutics is building its team across key areas including research, clinical development, quality, and clinical operations. If you’re looking for an opportunity to contribute to innovative oncology programs, we’d love to hear from you.

Take the next step in your career and discover opportunities at BriaCell: https://bit.ly/478ecPX

08/25/2026

BriaCell Chief Scientific Officer Miguel A. Lopez-Lago, PhD, highlights how Bria-MEL+ builds on the Company’s experience in metastatic breast cancer as BriaCell continues to expand its pipeline of personalized, cell-based immunotherapy vaccine candidates.

Learn more: https://bit.ly/4xjGX7p